Press release
Parainfluenza Virus Infection Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | AlloVir, Ansun Biopharma, Moderna Therapeutics
Parainfluenza Virus Infection Pipeline Analysis
Parainfluenza Virus Infection Pipeline constitutes 5+ key companies continuously working towards developing 5+ Parainfluenza Virus Infection treatment therapies, analyzes DelveInsight.
Parainfluenza Virus Infection Overview:
The human parainfluenza virus (HPIV) is a single-stranded, negative-sense RNA virus with an outer envelope, classified under the Paramyxoviridae family. HPIV is capable of causing both upper and lower respiratory tract infections (URTI and LRTI), particularly in young children under the age of 5, older adults, and those with weakened immune systems. While it shares some similarities with the influenza virus, HPIV is a distinct virus and can be clearly differentiated from myxoviruses, such as influenza. Some shared traits include limited antigenic overlap and poor replication in embryonated eggs.
The development of HPIV-related illness involves both host immune responses and viral activity. The virus attaches and fuses to host cells through two key surface proteins: hemagglutinin-neuraminidase (HN), which binds to sialic acid residues on the surface of respiratory epithelial cells, and fusion glycoproteins (F), which help merge the viral and cellular membranes. Once inside, actin and the cytoskeleton assist in the processes of viral transcription, maturation, and the transport of viral glycoproteins to the cell surface for further replication and spread.
Download our report @ https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Parainfluenza Virus Infection Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parainfluenza Virus Infection Therapeutics Market.
Key Takeaways from the Parainfluenza Virus Infection Pipeline Report
*
DelveInsight's Parainfluenza Virus Infection pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Parainfluenza Virus Infection treatment.
*
In April 2025, researchers at the University of Pennsylvania developed a clinical-grade antiviral chewing gum aimed at reducing viral loads of certain influenza A strains and herpes simplex viruses. While this innovation primarily targets influenza and herpes viruses, it represents a novel approach in antiviral therapies that could potentially be adapted for other respiratory viruses, including parainfluenza.
*
In March 2025, Decoy Therapeutics Inc. announced that its antiviral drug candidates, designed using the Imp3act platform, demonstrated promising activity against multiple viruses within the paramyxoviridae family, including human parainfluenza virus 3 (hPIV3). These candidates had previously shown effectiveness against respiratory syncytial virus and hPIV3.
*
Key Parainfluenza Virus Infection companies such as AlloVir, Ansun Biopharma, Moderna Therapeutics, and others are evaluating new drugs for Parainfluenza Virus Infection to improve the treatment landscape.
*
Promising Parainfluenza Virus Infection pipeline therapies in various stages of development include Oplunofusp, and others.
Parainfluenza Virus Infection Pipeline Analysis
The Parainfluenza Virus Infection pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Parainfluenza Virus Infection Market.
*
Categorizes Parainfluenza Virus Infection therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Parainfluenza Virus Infection drugs under development based on:
*
Stage of development
*
Parainfluenza Virus Infection Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Parainfluenza Virus Infection Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Parainfluenza Virus Infection Licensing agreements
*
Funding and investment activities supporting future Parainfluenza Virus Infection market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Parainfluenza Virus Infection Emerging Drugs
*
Oplunofusp: Ansun Biopharma
Parainfluenza Virus Infection Companies
There are over five major companies actively working on developing treatments for Parainfluenza Virus Infection. Among them, Ansun Biopharma has a drug candidate that has progressed to the most advanced development stage so far-Phase III clinical trials.
DelveInsight's report covers around 5+ products under different phases of Parainfluenza Virus Infection clinical trials like
*
Parainfluenza Virus Infection Late stage Therapies (Phase III)
*
Parainfluenza Virus Infection Mid-stage Therapies (Phase II)
*
Parainfluenza Virus Infection Early-stage Therapies (Phase I)
*
Parainfluenza Virus Infection Pre-clinical and Parainfluenza Virus Infection Discovery stage Therapies
*
Parainfluenza Virus Infection Discontinued & Inactive Therapies
Parainfluenza Virus Infection pipeline report provides the Parainfluenza Virus Infection therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Parainfluenza Virus Infection Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Parainfluenza Virus Infection Therapies and Key Parainfluenza Virus Infection Companies: Parainfluenza Virus Infection Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Parainfluenza Virus Infection Pipeline Therapeutic Assessment
- Parainfluenza Virus Infection Assessment by Product Type
- Parainfluenza Virus Infection By Stage
- Parainfluenza Virus Infection Assessment by Route of Administration
- Parainfluenza Virus Infection Assessment by Molecule Type
Download Parainfluenza Virus Infection Sample report to know in detail about the Parainfluenza Virus Infection treatment market @ Parainfluenza Virus Infection Therapeutic Assessment [https://www.delveinsight.com/sample-request/parainfluenza-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Parainfluenza Virus Infection Current Treatment Patterns
4. Parainfluenza Virus Infection - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Parainfluenza Virus Infection Late-Stage Products (Phase-III)
7. Parainfluenza Virus Infection Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Parainfluenza Virus Infection Discontinued Products
13. Parainfluenza Virus Infection Product Profiles
14. Parainfluenza Virus Infection Key Companies
15. Parainfluenza Virus Infection Key Products
16. Dormant and Discontinued Products
17. Parainfluenza Virus Infection Unmet Needs
18. Parainfluenza Virus Infection Future Perspectives
19. Parainfluenza Virus Infection Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Parainfluenza Virus Infection Pipeline Reports Offerings [https://www.delveinsight.com/report-store/parainfluenza-virus-infection-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parainfluenza-virus-infection-pipeline-analysis-and-clinical-trials-assessment-2025-by-delveinsight-allovir-ansun-biopharma-moderna-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parainfluenza Virus Infection Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | AlloVir, Ansun Biopharma, Moderna Therapeutics here
News-ID: 4165691 • Views: …
More Releases from ABNewswire
Marketing Expert Tony Hayes Reveals 18 Hidden Strategies Top Marketers Are Using …
Digital marketing strategist Tony Hayes releases comprehensive newsletter edition exposing the automation systems and AI-powered strategies elite marketers are leveraging to generate substantial income streams. The "Marketing X-Files" edition analyzes real-world case studies including TikTok Shop affiliates earning multiple 6-figures monthly, AI agents replacing $250K marketing teams, and faceless YouTube channels generating $20K in 87 days.
Digital marketing expert Tony Hayes has released a comprehensive analysis of 18 breakthrough strategies that…
QuoteIQ Revolutionizes Commercial Cleaning Industry with All-in-One Software Pla …
Fastest-Growing CRM in Home and Field Service Industries Announces Specialized Features for Janitorial, House Cleaning, and Facility Management Companies
SAVANNAH, GA - October 2, 2025 - QuoteIQ, the fastest-growing customer relationship management (CRM) platform for home and field service industries, today announced significant milestones in helping commercial cleaning businesses increase profitability, streamline operations, and scale their services. With a 300% year-over-year user growth rate, QuoteIQ has become the go-to software solution…
Matouk Family Dentistry Elevates Dental Care in South Houston with Comprehensive …
Matouk Family Dentistry in South Houston provides personalized, full-spectrum dental care-ranging from routine exams, fillings, crowns, root canals, and dentures to cosmetic treatments like whitening and implant restoration. Led by Dr. Christina Matouk, the practice is committed to comfort, accessibility, affordability, and continuity of care for families and emergency patients across Houston and neighboring areas.
South Houston, TX - October 2, 2025 - Matouk Family Dentistry [https://matoukfamilydentistry.com/?utm_source=chatgpt.com], conveniently located at 12929…
The Streets Tried to Break Him, the Music Helped Him Heal. Follow the Transition …
Artist Bio: YGG100
Image: https://www.abnewswire.com/upload/2025/10/a4cc0350de25f6a260f057df6144d5bb.PNG
Origin Story
YGG100, born and raised on the South Side of Chicago in the "wild wild 100's," comes from a background of gamblers and hustlers. Growing up in an environment of constant survival, he witnessed the streets firsthand - from selling drugs to gunplay - before making a full 360 turn in 2009 to dedicate his life to music. His journey includes surviving a street war between Black…
More Releases for Parainfluenza
Parainfluenza Virus Infection Market to Expand Significantly by 2034, States Del …
DelveInsight's "Parainfluenza Virus Infection Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology as well as the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
DelveInsight's Parainfluenza Virus Infection Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.
The latest healthcare forecast report…
Parainfluenza Virus Infection Market: Insights on Epidemiology, Treatments, and …
The Parainfluenza Virus Infection Market is projected to witness consistent growth throughout the forecast period (2024-2034). The Parainfluenza Virus Infection Market Size in the 7MM is expected to increase, driven by increasing Incident population.
Emerging therapies for Parainfluenza virus infection, including DAS181, ALVR106, and others, are expected to drive growth in the Parainfluenza virus infection market in the coming years.
DelveInsight has released a new report titled "Parainfluenza Virus Infection - Market…
Parainfluenza Virus Infection Market is expected to reach USD 1.15 billion by 20 …
Parainfluenza viruses (HPIVs) are a group of RNA viruses that cause respiratory tract infections, particularly in children, elderly patients, and immunocompromised individuals. HPIV infections are a leading cause of croup, bronchiolitis, and pneumonia, often requiring hospitalization in severe cases. Unlike influenza, there are currently no approved vaccines or specific antivirals for parainfluenza, making management largely supportive.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71751
Growing research in antivirals, monoclonal…
Parainfluenza virus infection Market: Epidemiology, Therapies, Companies, DelveI …
Parainfluenza virus infection therapies, such as DAS181, ALVR106, and others, are expected to boost the Parainfluenza virus infection Market in the upcoming years.
DelveInsight has launched a new report on "Parainfluenza virus infection - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Parainfluenza virus infection, historical and forecasted epidemiology as well as the Parainfluenza virus infection market trends in the United States, EU5 (Germany, Spain, Italy,…
Parainfluenza Virus Infection-Market Outlook report Assessment, Growth Trends, E …
It has been observed that, the global market for Parainfluenza Virus Infection-Market would be experiencing steady growth marked in million US$ by 2025. Such advancements can be attributed to the efforts put in by prime manufacturers operating in the global Parainfluenza Virus Infection-Market during the period 2028. All such statistics and figures are carefully enclosed in a recently uploaded research report titled “Parainfluenza Virus Infection-Market Insights, Epidemiology and Market” Forecast-2028,…
Human Parainfluenza Viruses Diagnostics Market will reach 940 million USD in 202 …
New report published by Global Info Research which offers insights on the global Human Parainfluenza Viruses Diagnostics market.
Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs.
Click…
